Trans-Pacific Partnership IP Provisions Relevant to Access to Medicines

Andrew S. Goldman, Esq.
Knowledge Ecology International
www.keionline.org
What is the TPP?
(according to USTR...)

Images from the USTR twitter feed leave a warm and cuddly impression.

Andrew S. Goldman / KEI
By the numbers:

12 Countries
(Australia, Brunei, Canada, Chile, Japan, Malaysia, Mexico, New Zealand, Peru, Singapore, United States, Vietnam)

7 years of negotiation

5000+ pages

127 pages of emails between U.S. government officials and corporate lobbyists returned via IP-Watch FOIA as of 2013 (http://keionline.org/node/1833)

Andrew S. Goldman / KEI
By the numbers…

6 of 12 TPP countries considered “developing” by the U.N.

$1,890 Vietnam GNI per capita (2014)

$19,100,000,000: Gilead 2015 sales on Sovaldi and Harvoni
(http://www.fiercepharma.com/story/gileads-hep-c-juggernaut-continues-q4-even-us-sales-fall/2016-02-02)

Andrew S. Goldman / KEI
By the numbers…

4 leaks of the IP Chapter

(3 wikileaks + 1 via KEI)
IP Chapter re A2M:
   Evergreening (patentable subject matter)
   Patent Term Adjustments
   *Sui Generis* Exclusivity (small molecules and biologics)
   Damages

Investment Chapter:
   Investor-State Dispute Settlement
Patent Evergreening
Article 18.37

“2. …each Party confirms that patents are available for inventions claimed as at least one of the following: new uses of a known product, new methods of using a known product, or new processes of using a known product. A Party may limit those new processes to those that do not claim the use of a product as such.”

“Typically, when you evergreen something, you are not looking at any significant therapeutic advantage. You are looking at a company’s economic advantage.”

--Dr. Joel Lexchin, Professor
York University School of Health Policy and Management

“2. With respect to a pharmaceutical product that is subject to a patent, each Party shall make available an adjustment [46] of the patent term to compensate the patent owner for unreasonable curtailment of the effective patent term as a result of the marketing approval process.”

“Unreasonable” = undefined

Footnote 46 provides that alternatively a Party may provide an analogous *sui generis* form of protection.
Sui Generis Exclusivity
Article 18.50 (small molecules)

1.(a)-(b): At least 5 years protection against generic manufacturer gaining marketing approval on basis of originator’s (i) safety/efficacy data or (ii) marketing approval. Runs from date of originator approval in the date of the TPP Party.

2.(a)-(b): Additional 3 year period of exclusivity where an existing product is approved for a new indication/use/method, or, alternatively, an additional five year period for new product containing a new chemical entity.
Sui Generis Exclusivity
Article 18.51 (biologics)

1.(a): a period of at least 8 years, or alternatively, (b) at least five years plus “other measures” to “deliver a comparable outcome in the market.”

TPP countries with ZERO exclusivity on biologics pre-TPP:
Brunei
Mexico
Peru
Vietnam
Damages
Article 18.74 (Civil and Administrative Procedures and Remedies)

“3. Each Party shall provide [109] that, in civil judicial proceedings, its judicial authorities have the authority at least to order the infringer to pay the right holder damages adequate to compensate for the injury the right holder has suffered because of an infringement of that person’s intellectual property right by an infringer who knowingly, or with reasonable grounds to know, engaged in infringing activity.

4. In determining the amount of damages under paragraph 3, each Party’s judicial authorities shall have the authority to consider, among other things, any legitimate measure the right holder submits, which may include lost profits, the value of the infringed goods or services measured by the market price, or the suggested retail price.”

[109] A Party may also provide that the right holder may not be entitled to any of the remedies set out in paragraphs 3, 5 and 7 if there is a finding of a non-use of a trademark…”

Andrew S. Goldman / KEI
Concerns re: Damages

Some U.S. laws specify how damages are to be calculated (actual damages, lost profits, etc.), sometimes setting the rate to zero.

Lack of carveout for statutory limitations (a la FN 109)

Some U.S. law examples utilizing “reasonable royalty”:
- Biologics Price Competition and Innovation Act (BPCIA)
Concerns re: Damages

Letter from Rep. Eshoo (D-CA) to Michael Froman, Oct 20 2015:

“…in some cases the ‘sole and exclusive’ remedy for patent infringement pertaining to biologics is a ‘reasonable royalty.’”

“I’m concerned that the TPP agreement’s language on damages in the IP Chapter provides no room for statutory limitations on damages…”

(www.keionline.org/node/2349)
Investment Chapter

Art. 9.1 (Definitions)

“investment means every asset that an investor owns or controls…Forms that an investment may take include:

... 

(f) intellectual property rights”

Art. 9.7 (Expropriation and Compensation)

“(5) This Article shall not apply to the issuance of compulsory licences granted in relation to intellectual property rights in accordance with the TRIPS Agreement, or to the revocation, limitation or creation of intellectual property rights, to the extent that the issuance, revocation, limitation or creation is consistent with Chapter 18 (Intellectual Property) and the TRIPS Agreement.

[19] For greater certainty, the Parties recognise that, for the purpose of this Article, the term ‘revocation’ of intellectual property rights includes the cancellation or nullification of those rights, and the term ‘limitation’ of intellectual property rights includes exceptions to those rights.”

Andrew S. Goldman / KEI
Recent/Ongoing ISDS Cases

TransCanada v United States
TC seeking $15 Billion for cancellation of Keystone XL pipeline (via NAFTA ISDS)

Eli Lilly v Canada
EL challenging Canada since 2013 under NAFTA ISDS ($500M) re: Canada invalidation of EL patents

Philip Morris v Australia
PM brought ISDS action against Australia in 2012 re plain packaging tobacco law. Just ended in Dec. 2015.
Political Reality?
U.S. implementing legislation timeline is tight
   Feb 4 signing
   → wait at least 30 days to introduce legislation
   → max 105 days from signing, ITC report to Congress on
   probable economic effects
   → Congressional consideration
Election Year…
Dem Candidates – all opposed
Republican Candidates – Trump opposes, Cruz somewhat back and forth, Kasich “PPT”

Andrew S. Goldman / KEI
What Could Have Been?

Delinkage (R&D costs // price)
Orphan Drug Tax Credit
Prize Funds
R&D Commitments
Transparency in Clinical Trial Data and R&D Costs